PT-141 (Bremelanotide): Melanocortin Receptor Research

PT-141, a cyclic heptapeptide melanocortin receptor agonist, is researched for central nervous system effects on arousal and related pathways.

PT-141 Research Updates

Phase 3 efficacy in female models by Sheryl Kingsberg at University Hospitals Cleveland showed significant endpoint improvements. Male function enhancement per Irwin Goldstein at Alvarado Hospital.

MC4R binding specificity per Victor J. Hruby at the University of Arizona. Nasal vs. subcutaneous comparisons by Palatin Technologies.

PT-141 Mechanisms

Central MC4R activation in hypothalamus; distinct from PDE5 inhibitor mechanisms. Derived from α-MSH analog Melanotan II.

PT-141 Directions

Dosing optimization for tolerability (nausea management). Combination approaches in dysfunction models.

Links

• [Female Phase 3](https://pubmed.ncbi.nlm.nih.gov/31693131/)
• [Male](https://pubmed.ncbi.nlm.nih.gov/14657536/)